加州 的 慢性淋巴性白血病 臨床試驗
33 項針對 慢性淋巴性白血病 的研究正在 加州 各地點尋找參與者。
加州 的城市
- Baldwin Park16 項研究
- San Diego10 項研究
- Los Angeles8 項研究
- Mountain View7 項研究
- Irvine6 項研究
- Orange5 項研究
- Long Beach4 項研究
- San Francisco4 項研究
- Anaheim3 項研究
- Sacramento3 項研究
- Burbank3 項研究
- Santa Monica3 項研究
官方研究文本（英文）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Baldwin Park, Baldwin Park
- Kaiser Permanente-Bellflower, Bellflower
- 還有 12 項
招募中3 期
65 歲及以上 · 所有性別 · 更新於 2026年10月2日 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- 還有 20 項
招募中觀察性研究歡迎健康志工
40 至 75 歲 · 所有性別 · 更新於 2026年10月2日 · NCT05334069A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
招募中1/2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月30日 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Baldwin Park, Baldwin Park
- Kaiser Permanente-Bellflower, Bellflower
- 還有 28 項
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月30日 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 115, Huntington Park
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月30日 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Uci Health Laguna Hills, Laguna Hills
- Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute, Palo Alto
- 還有 1 項
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
招募中1/2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- City of Hope National Medical Center, Duarte
- Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute, Palo Alto
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- UCLA Department of Medicine Hematologyoncology, Los Angeles
- Scripps Prebys Cancer Center, San Diego
- Pih Health Whittier Hospital, Whittier
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Kaiser Permanente Southern California, Irvine
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- 還有 8 項
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月24日 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Moores Cancer Center ( Site 0003), La Jolla
- Care Access - South Pasadena ( Site 0070), Pasadena
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月24日 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- UC Irvine, Orange
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年9月21日 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- City of Hope, Duarte
- Cedars-Sinai Medical Center, Los Angeles
- Scripps Health, San Diego
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月17日 · NCT07221500Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- City of Hope Comprehensive Cancer Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- University of California Davis Comprehensive Cancer Center, Sacramento
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月11日 · NCT07061951Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope National Medical Center, Duarte
招募中1/2 期
12 歲及以上 · 所有性別 · 更新於 2026年9月3日 · NCT04588922A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Pacific Cancer Medical Center, Inc, Anaheim
- TOI Clinical Research, Cerritos
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年8月17日 · NCT05254743A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- City of Hope, Duarte
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年8月17日 · NCT06528301Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
招募中1/2 期
13 至 90 歲 · 所有性別 · 更新於 2026年8月6日 · NCT06533579A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
招募中1 期歡迎健康志工
18 至 75 歲 · 所有性別 · 更新於 2026年7月28日 · NCT07020533A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年7月2日 · NCT05131022Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年6月22日 · NCT04545762A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- City of Hope National Medical Center, Duarte
- City of Hope National Medical Center, Irvine
- Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto
- 還有 1 項
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年5月19日 · NCT06588478Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年4月20日 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- 還有 1 項
招募中1/2 期
12 至 95 歲 · 所有性別 · 更新於 2026年4月15日 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis
- Valkyrie Clinical Trials /ID# 268151, Los Angeles
招募中3 期
18 歲及以上 · 所有性別 · 更新於 2026年4月9日 · NCT06428019Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Stanford Cancer Institute Palo Alto, Palo Alto
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年3月25日 · NCT05388006A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年3月20日 · NCT04830137Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- City of Hope at Long Beach Elm, Long Beach
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年3月13日 · NCT07218510CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
招募中2 期歡迎健康志工
18 至 75 歲 · 所有性別 · 更新於 2026年3月10日 · NCT06059391Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Moores Cancer Center at UC San Diego /ID# 230157, La Jolla
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年2月9日 · NCT04895436AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2025年12月10日 · NCT05602363A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
招募中2 期
18 至 80 歲 · 所有性別 · 更新於 2025年10月14日 · NCT06520098資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。